Pharmacy Learning Network

Key Takeaways: The US Food and Drug Administration (FDA) has issued a voluntary Class II recall for Diovan (valsartan) tablets, 160 mg. The affected batch has been identified as Lot AV5913C (expires June 2027). The recall was initiated by Novartis Pharmaceuticals due to failed dissolution specifications, a quality issue that is likely to cause temporary or medically reversible adverse health consequences or has a low probability of serious adverse health consequences.

Key Takeaways: The US Food and Drug Administration (FDA) has issued a voluntary Class I recall for Kian Pee Wan capsules. The affected batches are all lots within expiration, containing 71 bottles. The recall was initiated by Buy-Herbal due to the presence of undeclared drugs dexamethasone and cyproheptadine, a quality issue that is likely to cause serious adverse health consequences or death. Kian Pee Wan capsules are used to improve appetite and weight gain.

AMP_PAGE_VIEWPending Maximum Storage Duration: SessionType: HTML Local Storage AMP_remote_config_090786228dPending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_SR_START_#_#Pending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_URL_INFOPending Maximum Storage Duration: SessionType: HTML Local Storage EXP_090786228dPending Maximum Storage Duration: PersistentType: HTML Local Storage EXP_090786228d_DEFAULT_USER_PROVIDERPending Maximum Storage Duration:...

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Key Takeaways: The US Food and Drug Administration (FDA) has issued a voluntary Class II recall for dicyclomine hydrochloride tablets, 10 mg. The affected batch has been identified as Lot DMC125018A (expires July 2027), containing 6408 bottles. The recall was initiated by Aurobindo Pharma USA, Inc due to reports of empty capsules, a quality issue that is likely to cause temporary or medically reversible adverse health consequences and has a low probability of serious adverse health consequences.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Key Takeaways: The US Food and Drug Administration (FDA) has issued a voluntary Class I recall for cyclophosphamide injection, 1 g/vial and 2 g/vial. The affected batches have been identified as Lots C23019V1 (expires October 2026), C24015V1 (expires April 2027), and V24010V1 (expires March 2027), affecting 5541 vials. The recall was initiated by Sunny Pharmtech, Inc due to the presence of particulate matter, a quality issue that is likely to cause serious adverse health consequences or death.

Key Takeaways: Eli Lilly has filed 6 lawsuits against pharmacies, medical spas, and peptide sellers that it alleges are unlawfully marketing versions of its investigational obesity drug retatrutide before the product has received regulatory approval.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Key Takeaways: The US Food and Drug Administration (FDA) has issued a voluntary Class II recall for azelaic acid gel, 15%, 50 g. The affected batches have been identified as Lots 19260937A (expires February 2028), 19261225A and 19261185A (expiring March 2028), and 19261664A and 19261682A (expiring April 2028).